Refining Immunotherapy Approvals

Reviews and Approvals

Immunotherapy of Cancer

This article has no abstract.

NEW DRUG APPROVALS Opdivo for Melanoma

NEW DRUG APPROVALS Opdivo for Melanoma Nivolumab injection (Opdivo, BristolMyers Squibb) has received the FDA’s accelerated approval for the treatment of patients with unresectable or metastatic melanoma that has progressed after treatment with specific medications. Nivolumab is a monoclonal antibody that binds to the programmed death-1 (PD-1) receptor and blocks its interaction with ligands PD...

NEW DRUG APPROVALS Kybella for Submental Fat

NEW DRUG APPROVALS Kybella for Submental Fat Deoxycholic acid (Kybella, Kythera Biopharmaceuticals Inc.) has received FDA approval to treat moderate-to-severe fat below the chin, called submental fat. The product is not approved or recommended to treat fat outside of the submental area. Kybella is identical to the deoxycholic acid produced in the body, which helps the body absorb fats. A cytoly...

NEW DRUG APPROVALS Farydak for Multiple Myeloma

NEW DRUG APPROVALS Farydak for Multiple Myeloma The FDA has approved panobinostat (Farydak, Novartis) to treat multiple myeloma (MM), which kills more than 10,000 mostly older Americans a year. Panobinostat inhibits the activity of histone deacetylases, which may slow the overdevelopment of plasma cells or cause these cells to die. Panobinostat is intended for patients who have received at leas...